Harrow jumps on predicting Q4 sales above estimate
18/03/2025 09:30
** Harrow HROW.O soars ~24% to $28.90 premarket ** Eye-drug maker sees prelim Q4 sales in the $65 mln-$67 mln range; analysts' estimate stands at $58.4 mln, per data compiled by LSEG ** Forecasts 2025 sales to be more than $280 mln, slightly below analysts' estimate of $281.2 mln ** Expects its FDA-approved, high-profit branded products to be the main driver of growth this year ** HROW gained ~181% in 2024 (Reporting by Kamal Choudhury in Bengaluru) ((Kamal.Choudhury@thomsonreuters.com;))
Recent news on Harrow
See all newsHarrow, Inc. reports results for the quarter ended June 30 - Earnings Summary
Harrow Q2 revenue slightly beats estimates
Viatris raises annual profit forecast on branded drug strength
Brief: Harrow Re-Launches Verkazia® (Cyclosporine Ophthalmic Emulsion) 0.1% For Vernal Keratoconjunctivitis, Addressing Significant Unmet Need In Pediatric Eyecare
Harrow Q1 revenue misses analyst estimates